

STUDY ON THE SOLUBILITY, DISSOLUTION, STABILITY AND MICROMETRIC PROPERTIES OF OMEPRAZOLE VIA CO CRYSTALLIZATION TECHNIQUES

Pallavi Bhalchandra Duse ,

Dr. Kailaspati Prabhakar Chittam,

Research Scholar, School of Pharmacy,

Research Supervisor, School of Pharmacy,

Glocal University Saharanpur (U.P)

Glocal University Saharanpur (U.P)

ABSTRACT:

Omeprazole, a proton-pump inhibitor used in peptic ulcers, gastro-oesophageal-reflux disorder, Zollinger-Ellison syndrome and in H.pylori infections. The omeprazole is unstable at acidic pH, undergoes degradation in stomach. To prevent the degradation in stomach, dosage forms are supplied as enteric-coated tablets or granules encapsulated in gelatin capsules. The efficiency of such dosage forms depends upon the extent of coating, solubility of coating material, type of dosage forms; in addition this it is insoluble in water, having poor bioavailability. To overcome these major drawbacks of omeprazole, a novel technique: cocrystallization was attempted, to produce a stable, enhancement in solubility and improved micromeritic properties of omeprazole. Co-crystals consists of API and a stoichiometric amount of a pharmaceutically acceptable co-crystal former. Pharmaceutical Co-crystals are non-ionic supramolecular complexes and can be used to address physical property issues such as solubility, stability and bioavailability in pharmaceutical development without changing the chemical composition of the API. Co-crystal is a crystalline entity formed by two different or more molecular entities where the intermolecular interactions are weak forces like hydrogen bonding and π - π stacking. FTIR revealed that there is no formation of hydrogen bonding between drug and co-former; hence it states that co-crystals are not formed, but XRD and DSC states that there is a formation of some physical interaction, partial crystalline and amorphous form which is a new crystal lattice.

KEYWORDS: *co-crystallization, dissolution behaviour, micromeritic properties.*

INTRODUCTION:

Omeprazole, a proton-pump inhibitor is widely prescribed for the treatment of peptic ulcer, Zollinger- Ellison syndrome, Gastro-oesophageal reflux disease (GERD), H.pylori infection and NSAID associated ulcers. Its oral bioavailability (40-50%) in humans is poor, due to acid sensitivity and first pass metabolism.

Attempts were made earlier to improve the bioavailability by formulating it as enteric-coated granules encapsulated in gelatin shell and enteric-coated tablets etc. The efficiency of such dosage forms depends upon the number of parameters such as extent of coating, solubility of coating material and type of dosage form[1]

The maximum development and interest area is being diverted to co-crystallization. Co-crystals are homogeneous solid phases containing two or more neutral molecular components in a crystal lattice with defined stoichiometric proportions, which are solids at room temperature and are held together by weak interactions, mainly hydrogen bonding. Pharmaceutical co-crystals can enhance the essential properties of the APIs such as flowability, chemical stability, compressibility and hygroscopicity. Co-crystallization can be achieved only when the physiochemical properties like Hygroscopicity, solubility, micromeritic properties and compaction behaviour of the formulation is to be improved at one step. Co-crystals basically consists of two components that are the API and the cofomer, the co-former can be any other excipient or API which when given in combination reduces the dose and also the side effects. Changing the co-former will also changes the pharmaceutical properties, chemical stability, bioavailability, solubility, melting point,moisture uptake, dissolution.

As mentioned earlier co-crystallization is the most dynamically developing group of solid pharmaceutical substances, it is a very vast area. Hence, they can be divided into co-crystal anhydrides, co-crystal hydrates (solvates), anhydrides of co-crystals of salts and hydrates (solvates) of co-crystals of salts [2, 3].




Figure.1 Comparison of co-crystals with other solid forms

Table .1 Methods used for co-crystal preparation [10]

Solid based methods	Solution based methods	Supercritical fluid methods	Electrically assisted methods
Co-grinding/dry grinding	Isothermal slurry conversion	Supercritical slurry crystallization	Sono-crystallization
Solvent drop grinding	Slow evaporation	Supercritical anti-solvent (SAS) and gas anti-solvent (GAS)	Microwave assistance
Extrusion	Assisted evaporative co-crystallization	Supercritical assisted spray drying	
Hot melt extrusion	Spray drying		
High shear wet granulation	Reactive co-crystallization		
	Cooling co-crystallization		
	Anti solvent addition		

MATERIALS AND METHODS:

Materials:

Omeprazole (USP) was obtained as a gift sample from Rawchem Laboratories Pvt. Ltd. (Hyderabad, India).PVP, magnesium chloride, sodium bicarbonate, Methanol, Ethanol, Acetone, 2-propanol, Sodium dihydrogen orthophosphate dihydrate, Disodium hydrogen orthophosphate dihydrate (AR grade) were obtained from different commercial suppliers.

Methods:

Experimental attempts to Prepare omeprazole Cocrystals:

To prepare omeprazole co-crystal, a best co-former should be selected first with hydrogen bonding donor and acceptor ability. All the dicarboxylic acids, esters, ethers, some drugs and excipients can have good conformer character. But omeprazole is a basic drug, it is unstable in acidic medium, hence co-former must be a basic compound with donor, acceptor ability. Cogrinding method, solvent drop grinding method, slurry crystallization method, slow evaporation method were failed due to instability, hygroscopicity, photosensitivity and thermolebility of omeprazole. Then basic compounds were selected and preparation method was optimized and finalized to anti solvent addition method.

Table. 2 Experiments attempted to make co-crystals of omeprazole

Compound	Co-formersattempted	Method of preparation	Inference
OMEPRAZOLE	Di carboxylic acids	Co-grinding	Unstable preparation
	PVP	Anti solvent addition*	Stable crystallinesubstance obtained.
	PVP	Co-grinding	Unstable preparation
	PVP	Solvent drop grinding	Unstable preparation
	Calcium carbonate	Slow evaporation	Unstable preparation
	Magnesium carbonate	Co-grinding	No crystal formed

	PEG	Co-grinding	No crystal formed
	Sodium carbonate	Slurry crystallization	Unstable preparation
	PVA	Co-grinding	Unstable preparation

Method of crystals preparation:

Anti-solvent addition method:

Pharmaceutical crystals of omeprazole were prepared with PVP as co-former, magnesium chloride and sodium bicarbonate as basic substances for maintaining stability in basic pH with different solvents like acetone, methanol, ethanol, 2-propanol by anti solvent addition method. crystal was prepared by dissolving 1:1 molar ratio of omeprazole and PVP in 10ml of solvents separately followed by addition of both solutions to magnetic stirrer, allow to mix thoroughly for 20 min, 20 ml of 2% magnesium chloride solution (cool water at 10°C -20°C) serves as anti-solvent is added slowly to the preparation, a turbidity is formed initially gradually it produces precipitate allow to stir continuously for about 2 hrs. Then filtered and dried at 40°C and stored in vials at cool and dark place.

Characterization studies of prepared crystals:

Melting point:

Melting point of pure omeprazole, co-formers and cocrystals were obtained by capillary method using liquid paraffin. The capillary filled with drug powder was placed in melting point apparatus and then liquid paraffin was heated, then drug is melt the melting point of drug powder was noted.

Differential Scanning Calorimetry (DSC):

Thermal analysis of omeprazole, co-former and prepared crystal were recorded individually on DSC (Q200), Waters. The samples were scanned at 10°C/min over a temperature range of 50^o- 400^oC with nitrogen purging in aluminium pan.

Fourier Transform Infrared (FT-IR) Studies:

FT-IR of pure omeprazole and prepared crystals spectra were recorded individually by a Spectrum RXI, Perkin Elmer FTIR spectrophotometer by mixing them with potassium bromide. Scans were recorded in the range of 400-4000 cm⁻¹ at spectral resolution of 4 cm⁻¹.

Powder X-Ray Diffraction:

The X-ray diffractogram were generated using a Bruker diffractometer D8 Advance. Multiscans over 10-60 minutes were employed over the 2θ- range 10-80^o, with a scan speed 4^o/min.

RESULTS AND DISCUSSION:

Table 3. physical characterizations studies of preparations with different basic compounds and solvents.

S. NO	CODE	CO-CRYSTAL COMPONENTS	2% BASIC COMPOUND	SOLVENT	MELTING POINT (°C)	SOLUBILITY mg/ml
1.	CO 1	Omeprazole + PVP	NaHCO ₃	Ethanol	142	0.794
2.	CO 2*	Omeprazole + PVP	MgCl ₂	Ethanol	135	1.0*
3.	CO 3	Omeprazole + PVP	NaHCO ₃	Acetone	137	0.822
4.	CO 4	Omeprazole + PVP	MgCl ₂	Acetone	135	0.799
5.	CO 5	Omeprazole + PVP	NaHCO ₃	Methanol	145	0.810
6.	CO 6	Omeprazole + PVP	MgCl ₂	Methanol	134	0.832
7.	CO 7	Omeprazole + PVP	NaHCO ₃	2-Propranol	144	0.816
8.	CO 8	Omeprazole + PVP	MgCl ₂	2-Propranol	136	0.438
9.	-----	Omeprazole	-----	-----	146	0.31

*Mark is denoted for the significant in the solubility and selected for preparation of crystals.

From the table 2, solubility and melting point data of different preparations were reported. CO 2 code preparation is having enhanced in solubility when compared with pure omeprazole. Thus it is chosen for further characterizations studies and dissolution studies.

Melting Point:

Discussion

Melting point is amongst the physicochemical properties of co-crystals. It is the temperature of solid and liquid phase equilibrium. This test was used as a preliminary test for confirmation of co-crystal formation. When the co-crystals are formed the melting point changes and comes in between the melting point of two individual molecules. If such results are obtained it can be confirmed that the co-crystals are formed.[9] It was found that the melting point of the crystals 135 °C showed a significant deviation with respect to the melting point of pure drug omeprazole 146°C and the individual co-former PVP 174°C indicating there must be some interactions between pure and co-former. [3]

Characterization by DSC




Figure 2. DSC of omeprazole-PVP crystals (a) pure omeprazole (b)

DISCUSSION:

From the fig 2 DSC thermograms, it was observed that the prepared crystals were different in pattern and intensity, as compared to pure omeprazole, which indicates their interaction. This shift in the melting point is due to the change in crystal lattice of the omeprazole in presence of co-former, forming a relatively different crystal lattice. The DSC thermogram of pure omeprazole(b) shows sharp melting peak at 122.5°C while DSC scan of their prepared crystals (a) shows a large broad peak at 72.7°C followed by another quite broad peak at 359°C depicting that melting peak of both omeprazole have shifted to lower and PVP have shifted to higher temperatures. These changes occurred as a consequence of interaction induced by thermal energy between the drug and the co-former, during the DSC scan of sample. The DSC thermogram for omeprazole- PVP crystal shows a broad peak at 72.7°C followed by a sharp melting peak at 359°C this DSC scan of crystals suggesting the formation of a new phase.

Fourier Transform Infrared (FT-IR) Studies:





Figure 3. FTIR spectrum of omeprazole –PVP crystals (a) and pure omeprazole (b)

DISCUSSION:

From the fig 3 FTIR patterns of pure omeprazole(b) shows characteristic absorption at 1456 C-H stretching of methyl groups, 1353 of S=O stretching of sulfinyl group, 1296 of C-N stretching for aromatic amine. But there is a change in the functional groups present in the prepared crystals (a) compared to that of pure omeprazole drug, absorption at 2923 of C-H stretching of alkanes, 1701 of C=O stretching of conjugated acids, 1421 O-H stretching of alcoholic group, 1459 C-H stretching of methyl groups, 1256 stretching of C-O aromatic esters showing presence of new bond formation in the optimized crystals. But it confirms no formation of hydrogen bonding between drug and the co-former. Thus it formed a new form of crystal lattice.

Powder X-Ray Diffraction

**CONCLUSION:**

The omeprazole-PVP optimized crystals were prepared successfully using co-former PVP, magnesium chloride as basic compound by anti-solvent addition method. These crystals were analytically characterized by melting point, FTIR, DSC and XRD. Results of studies reveals that formation of new crystal phases due to physical and chemical interactions between API and co-former, but by the FTIR results it was confirmed that there is no formation of co-crystals. Prepared crystals showed better solubility, dissolution and micromeritic properties as compared to pure omeprazole. By the stability studies it can be concluded that at $25\text{ }^{\circ}\text{C} \pm 2\text{C} / 60\%$ condition have good stability than the $40 \pm 2\text{ }^{\circ}\text{C} / 75\% \text{ RH} \pm 5\% \text{ RH}$. Many attempts were made to produce a stable, novel crystalline form of omeprazole to overcome all the major drawbacks of drug, but it failed in preparation of cocrystals by a novel particle engineering technique: cocrystallization. Further investigations were on progress to produce at most best formulation.

REFERENCES

1. Rama Nargund and A R Kulkarni, Synthesis, characterization and antiulcer study of ph-sensitive microspheres. scholars research library. Der Pharmacia Lettre, 2011, 3(6):82-89
2. Nanjwade and Meenaxi M. Maste. New trends in the cocrystallization of active pharmaceutical ingredients. Journal of Applied Pharmaceutical Science 01 (08); 2011: 01-05.
3. Kushal Shah, Sheetal Borhade, Vaishali Londhe. Utilization of cocrystallization for solubility enhancement of a poorly soluble antiretroviral drug – Ritonavir. International Journal of Pharmacy and Pharmaceutical Sciences Volume 6, Issue 2, 2014
4. Upadhyay N, Shukla T P, Mathur A, Manmohana, Pharmaceutical co-crystal: An emerging approach to improve physical property. International Journal of Pharmaceutical Sciences Review and Research, Volume 8, Issue 1, May – June 2011; Article-026
5. Higuchi T, Connors K. Phase-solubility techniques. Advances in Analytical Chemistry and Instrumentation, 4, 1965, 117-212
6. Renu Chadha, Anupam Saini, Poonam Arora, Somnath Chanda. Co-crystals of efavirenz with selected cofomers: preparation and characterization. International Journal of Pharmacy and Pharmaceutical Sciences Vol 4, Issue 2, 2012
7. Altaf Ahmad Najar and Yasser Azim. Pharmaceutical Co-Crystals: A New Paradigm of Crystal Engineering. Journal of the Indian Institute of Science VOL 94:1 Jan.–Mar. 2014 journal.iisc.ernet.in
8. Sulbha R. Fukte, Milind P. Wagh, Shilpi Rawat. Co-former selection: An important tool in co-crystal formation. International Journal of Pharmacy and Pharmaceutical Sciences Issue- 0975-1491 Volume 6, Issue 7, 2014
9. Tanvee Patole and Ashwini Deshpande. Co-crystallization-a technique for solubility enhancement. International Journal of Pharmaceutical Sciences and Research, 2014; vol. 5(9): 3566-3576
10. M K-Jafari, Luis P, G M. Walker, and D M. Croker. Creating Cocrystals: A Review of Pharmaceutical Co-crystal Preparation Routes and Applications. Crystal Growth Desgin-2018
11. Mandava V. Basaveswara Rao, B.C.K. Reddy, T. Srinivasa Rao. Dissolution test for omeprazole pellets 8.5% (high dissolution): optimization and statistical analysis. RJC Rasayan J. Chem vol.1, no.3 (2008), 618-619.
12. S. Shahid Mohammed, G. Venkatarajagopal Reddy, K. Viswaganga Pranush., Comparison of solubility improvement of cefixime and omeprazole magnesium by solid dispersion and slugging method. International Journal of Research in Pharmaceutical and Nano Sciences. 3(1), 2014, 50 - 60.

13. Y. Divya Bharathi and V.B. Rajesh. Enhancement solubility of lovastatin drug by using liquid-solid technique. World Journal of Pharmaceutical Research Volume 6, Issue 17, 567-587.
14. Sonawane Aravind R, Rawat Swati S, Janolkar Nandkishor N. Insights of Dosage form Design: Polymorphs and Co-crystals. Asian Journal of Biomedical and Pharmaceutical Sciences; 03 (27); 2013; 1-8.
15. Sirisha Mittapally and Arifa Banu. Formulation and evaluation of omeprazole nanoparticles by using natural polymers. The Pharma Innovation Journal 2016; 5(10): 111-117